Medgenics: EHA 2015 (Medgenics) - Jun 17, 2015 - “A total of 9 patients have been implanted. 7 out 8 evaluable patients demonstrated a good initial response with reticulocytosis and adequate Hb”; “Thus far, 5/6 patients in the low dose cohort had 5 or more months of TARGTEPO secretion with stable Hb response”
P1/2 data • Biosimilar
|